antilichaamscreening

Antilichaamscreening, also known as anti-Li screening, is a diagnostic technique used to detect the presence of antibodies against the Li antigen, which is a component of the Rh blood group system. This screening is particularly relevant in the context of blood transfusions and pregnancy, as it helps to identify potential incompatibilities that could lead to hemolytic reactions.

The Li antigen is found on the surface of red blood cells and is a part of the Rh system, which includes the D, C, E, and c antigens. The presence of anti-Li antibodies in a recipient's blood can cause the recipient's immune system to attack the donor's red blood cells, leading to a hemolytic transfusion reaction. Similarly, in pregnancy, the presence of anti-Li antibodies in the mother's blood can cause the mother's immune system to attack the fetus's red blood cells, potentially leading to hemolytic disease of the newborn.

Antilichaamscreening is typically performed using an indirect antiglobulin test (IAT). In this test, the recipient's serum is mixed with Li-positive red blood cells, and then an antiglobulin reagent is added. If anti-Li antibodies are present, they will bind to the Li-positive red blood cells, and the antiglobulin reagent will bind to the antibodies, forming a visible agglutination pattern.

The results of antilichaamscreening are crucial in determining the compatibility of blood for transfusions and in managing pregnancies where Rh incompatibilities are a concern. If anti-Li antibodies are detected, appropriate measures can be taken to prevent or mitigate potential complications.